Kelsey Schwensen

发表

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

A. Godwin, B. Kimler, Yen-Yun Wang, 2022, NPJ breast cancer.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

L. Esserman, S. Edge, L. Pusztai, 2021, The Lancet. Oncology.

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

A. Godwin, B. Kimler, I. Mayer, 2021, Clinical Cancer Research.

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).

A. Godwin, R. Salgado, R. Madan, 2022, Journal of Clinical Oncology.

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

A. Godwin, B. Kimler, Yen-Yun Wang, 2022, npj Breast Cancer.

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

A. Godwin, B. Kimler, Q. Khan, 2023, npj Breast Cancer.

Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore

L. Esserman, L. Pusztai, C. Caldas, 2021 .

Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

A. Godwin, B. Kimler, I. Mayer, 2021 .